Last updated: August 1, 2026
Aciphex is the brand name for rabeprazole sodium, a proton-pump inhibitor (PPI) approved for acid-related gastrointestinal disorders. Its U.S. exclusivity has ended, generic rabeprazole is widely available, and no active clinical development program is materially supporting the branded product. Commercial value has shifted from Aciphex to generic rabeprazole and combination products.
The main business risks are generic price erosion, substitution by other PPIs, and the absence of meaningful patent protection. The main residual opportunities are low-cost manufacturing, hospital and international tenders, pediatric formulations, and combination regimens for Helicobacter pylori eradication.
What is Aciphex and how does rabeprazole work?
Aciphex contains rabeprazole sodium, a substituted benzimidazole PPI. It suppresses gastric acid secretion by irreversibly inhibiting the gastric hydrogen-potassium ATPase, commonly called the proton pump, in gastric parietal cells.
The FDA-approved U.S. indications include:
- Short-term treatment of duodenal ulcers.
- Maintenance of healing of duodenal ulcers.
- Treatment of gastroesophageal reflux disease (GERD).
- Maintenance of healing of erosive or ulcerative GERD.
- Treatment of symptomatic GERD in adults.
- Healing and maintenance of healing of erosive GERD in pediatric patients aged 1 to 11 years, depending on dosage and labeling.
- Eradication of Helicobacter pylori in combination with amoxicillin and clarithromycin.
- Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
Aciphex delayed-release tablets are generally administered once daily. The product is enteric-coated because rabeprazole is acid-labile.
How does Aciphex compare with other PPIs?
Rabeprazole competes with omeprazole, esomeprazole, lansoprazole, dexlansoprazole and pantoprazole. Clinical differences among PPIs are usually less important than price, dosing convenience, formulary position and prescriber familiarity.
| Drug |
Brand |
Generic availability |
Primary commercial position |
| Rabeprazole |
Aciphex |
Yes |
Low-cost generic PPI |
| Omeprazole |
Prilosec |
Yes |
Broadest generic and OTC presence |
| Esomeprazole |
Nexium |
Yes |
Large OTC and prescription franchise |
| Pantoprazole |
Protonix |
Yes |
Strong institutional and generic use |
| Lansoprazole |
Prevacid |
Yes |
Generic and OTC availability |
| Dexlansoprazole |
Dexilant |
Yes, but less mature |
Differentiated dual delayed-release formulation |
Rabeprazole has pharmacokinetic characteristics that may offer advantages in certain patients, including relatively limited dependence on CYP2C19 metabolism compared with some other PPIs. Those differences have not preserved Aciphex’s brand pricing after generic entry.
What is the FDA regulatory status of Aciphex?
Aciphex received U.S. approval in 1997. Eisai developed the product, and Johnson & Johnson’s Janssen unit was involved in U.S. commercialization under historical licensing and co-promotion arrangements. The product was approved as a delayed-release tablet and later received pediatric labeling and other indication expansions.
The FDA Orange Book identifies Aciphex and generic rabeprazole sodium delayed-release tablets as approved products. The regulatory market is mature, with multiple abbreviated new drug application products.
What clinical trials are active for Aciphex?
No active, late-stage clinical trial program is known to be supporting a new Aciphex indication, a new rabeprazole mechanism, or a branded life-cycle expansion. Rabeprazole may appear in investigator-sponsored studies or combination-treatment trials, particularly involving H. pylori, GERD, gastrointestinal bleeding or acid suppression, but those studies do not represent a meaningful branded Aciphex development program.
The original clinical evidence base established efficacy for acid suppression, ulcer healing, GERD and hypersecretory conditions. Current clinical research is concentrated on:
- Comparative PPI effectiveness.
- H. pylori eradication combinations.
- PPI deprescribing and long-term safety.
- Refractory GERD.
- Gastrointestinal bleeding and perioperative acid suppression.
- Pediatric acid-related disorders.
- Treatment strategies involving potassium-competitive acid blockers such as vonoprazan.
What are the important clinical-trial developments for rabeprazole?
Rabeprazole remains clinically relevant in H. pylori eradication regimens and GERD treatment, but trial activity has not translated into significant proprietary value for Aciphex. Newer H. pylori combinations increasingly use vonoprazan or branded fixed-dose products, creating competitive pressure on PPI-based regimens.
The FDA approved Voquezna Triple Pak and Voquezna Dual Pak, both based on vonoprazan, for H. pylori eradication in adults in 2022. Vonoprazan is a potassium-competitive acid blocker and competes with PPI-based treatment approaches. [1]
When does Aciphex lose exclusivity?
Aciphex lost practical U.S. market exclusivity years ago. The original composition and product patents have expired, and generic rabeprazole is established in the market.
| Exclusivity category |
Aciphex status |
| New chemical entity exclusivity |
Expired |
| Original composition patents |
Expired |
| Original delayed-release product protection |
Expired |
| Pediatric exclusivity |
Expired |
| FDA approval exclusivity |
No current meaningful branded exclusivity |
| Generic competition |
Established |
| Biosimilar exposure |
Not applicable |
Rabeprazole is a small molecule, so it is subject to the ANDA generic pathway rather than the biosimilar pathway. The key legal route for generic entrants was the Paragraph IV certification process against listed patents, but that process is no longer a major barrier to market entry for rabeprazole.
What patents protect Aciphex?
The principal Aciphex patent estate covered rabeprazole sodium, pharmaceutical compositions and delayed-release oral dosage forms. Representative historical U.S. patents associated with rabeprazole include U.S. Patent No. 5,045,552 and related patent-family filings covering substituted benzimidazole compounds and pharmaceutical use.
The commercially relevant patent landscape is now historical rather than blocking:
| Patent category |
Commercial relevance |
| Rabeprazole compound patents |
Expired |
| Salt and formulation patents |
Expired or no longer commercially blocking |
| Delayed-release tablet patents |
Expired |
| GERD and ulcer method-of-use patents |
Expired |
| Pediatric use patents |
Expired |
| Manufacturing process patents |
May remain relevant in isolated jurisdictions, but do not restore U.S. brand exclusivity |
Patent expiration dates vary by jurisdiction and by patent family. Patent-term adjustments, terminal disclaimers and national-phase prosecution can produce different dates. The U.S. market, however, has already transitioned to generic competition.
How many patents cover Aciphex?
Historical patent families covering rabeprazole and Aciphex-related formulations include compound, salt, formulation, process and method-of-use claims. The number of documents depends on whether the analysis counts only issued U.S. patents, worldwide family members, continuations or abandoned applications.
The commercially meaningful conclusion is that no active Aciphex patent family currently creates a broad U.S. barrier to generic rabeprazole delayed-release tablets. Remaining patents, if any, are likely to be narrow, jurisdiction-specific or directed to manufacturing and formulation details rather than the core product.
What is the Orange Book status of Aciphex?
Aciphex is listed in the FDA Orange Book as a prescription drug product, with generic rabeprazole products also listed. Orange Book listings historically supported patent certifications by ANDA applicants.
The current Orange Book position does not provide Aciphex with effective market protection because:
- The core product has long faced generic substitution.
- Multiple generic manufacturers have received FDA approval.
- Brand prescribing is limited.
- The product lacks an active exclusivity period that would prevent ANDA competition.
Orange Book status should be distinguished from commercial protection. A listed patent can create litigation risk, but expired or non-blocking patents do not preserve brand share.
Which companies challenged Aciphex patents?
Generic manufacturers, including major ANDA filers and international generic companies, entered the rabeprazole market after challenging or designing around historical Aciphex patent claims. Publicly reported generic competition involved companies such as Teva, Dr. Reddy’s Laboratories, Mylan, Sandoz and other manufacturers active in generic PPIs.
The relevant litigation period occurred before broad generic availability. Current competitive analysis is more focused on FDA approval, pricing, supply reliability and contract access than on active Paragraph IV litigation.
What patent litigation affects Aciphex?
No major active U.S. patent litigation is currently known to materially restrict generic rabeprazole supply or delay market access. Historical litigation centered on whether generic delayed-release rabeprazole products infringed Aciphex formulation and product patents.
The litigation risk profile is now low for the branded product and moderate for manufacturers that may rely on narrow formulation or process patents in selected countries. Generic companies should still conduct freedom-to-operate reviews for:
- Enteric-coating systems.
- Tablet layering and release profiles.
- Rabeprazole salt forms.
- Manufacturing processes.
- Fixed-dose H. pylori combinations.
- Pediatric granules or suspension systems.
What formulation patents protect rabeprazole?
Rabeprazole is acid-sensitive, so the main technical challenge is protection from gastric degradation before intestinal release. Historical and potentially residual formulation claims may cover:
- Enteric-coated tablets.
- Alkaline stabilizers.
- Multilayer tablet structures.
- Delayed-release pellets.
- Capsules containing coated granules.
- Pediatric sprinkle or suspension formats.
- Specific dissolution profiles.
- Manufacturing processes that improve stability.
The core Aciphex tablet formulation is no longer a strong U.S. exclusivity platform. A new formulation could obtain patent protection if it provides a demonstrable technical advantage, such as improved stability, easier pediatric administration or a clinically relevant release profile. A reformulation would still face a mature generic market and limited physician willingness to pay.
What method-of-use patents cover Aciphex?
Historical method-of-use protection covered treatment of acid-related disorders, including GERD, ulcers, hypersecretory conditions and H. pylori infection. These uses are now clinically established and generally unprotected by enforceable U.S. Aciphex patents.
Potential new method claims could involve:
- Specific dosing in refractory GERD.
- Use in defined patient genotypes.
- Combination use with antibiotics or potassium-competitive acid blockers.
- De-escalation or intermittent treatment strategies.
- Treatment of selected extraesophageal symptoms.
Such claims would face enablement, written-description, obviousness and infringement challenges. Method-of-use patents are unlikely to restore the former Aciphex commercial franchise.
What are the generic entry risks for Aciphex?
Generic entry risk is already realized rather than prospective. The branded product faces permanent price pressure from:
- FDA-approved generic rabeprazole.
- Therapeutic substitution by omeprazole and pantoprazole.
- OTC availability of competing PPIs.
- Pharmacy benefit manager formulary controls.
- Hospital and health-system purchasing.
- Low switching costs for prescribers.
- Limited differentiation in routine GERD treatment.
The main risk for generic manufacturers is not patent blockage. It is margin compression and supply competition.
What generic launch scenarios exist?
| Scenario |
Probability |
Commercial effect |
| Continued multi-source generic supply |
High |
Stable low prices and limited brand share |
| Further price erosion |
High |
Lower manufacturer margins |
| Supply consolidation |
Moderate |
Potential short-term price increases during shortages |
| New pediatric or combination formulation |
Low to moderate |
Niche revenue opportunity |
| Brand revival through reformulation |
Low |
Requires meaningful clinical differentiation |
| Large-scale patent-driven delay |
Very low |
No broad U.S. blocking estate identified |
How strong is the Aciphex patent estate?
The Aciphex patent estate is weak for current U.S. commercial protection. Its historical estate was valuable because it protected a novel PPI and delayed-release oral product during the launch and growth period. That protection has expired.
| Strength factor |
Assessment |
| Core molecule protection |
Weak or expired |
| Tablet formulation protection |
Weak for broad market claims |
| Method-of-use protection |
Weak or expired |
| Manufacturing protection |
Potentially relevant in narrow jurisdictions |
| Regulatory exclusivity |
None of commercial significance |
| Generic litigation leverage |
Low |
| Life-cycle management potential |
Limited without new clinical differentiation |
What is the Aciphex market size and revenue exposure?
Aciphex’s historical revenue was driven by prescription branded sales during the period before generic rabeprazole became broadly available. Current brand revenue is substantially lower because most prescriptions are filled with generic rabeprazole or replaced by other PPIs.
Public company reporting generally does not provide a standalone current Aciphex revenue line. The product is often grouped within broader pharmaceutical or gastrointestinal portfolios, which limits precise brand-level revenue reconstruction.
The economic value is now concentrated in generic rabeprazole:
- Low unit prices.
- High prescription volume relative to brand value.
- Limited pricing power.
- Contract-driven procurement.
- Potential volume through international markets.
- Modest opportunity in differentiated dosage forms.
What is the Aciphex market projection?
The branded Aciphex market should remain flat to declining over the medium term. A reasonable base-case projection is:
| Period |
Brand Aciphex outlook |
Generic rabeprazole outlook |
| 2024-2025 |
Continued erosion |
Stable volume, price pressure |
| 2026-2028 |
Niche maintenance product |
Mature, low-growth generic market |
| 2029 onward |
Limited residual sales |
Ongoing substitution by lower-cost PPIs |
The broader PPI market may grow modestly in value because of population aging, persistent GERD prevalence and increased diagnosis. That growth is unlikely to benefit Aciphex proportionately because generic competition captures most incremental volume.
A material upside case would require a new rabeprazole product with a differentiated delivery system, pediatric positioning, combination regimen or evidence-based benefit in a defined patient population.
What licensing deals involve Aciphex?
Historical commercialization involved Eisai and Janssen-related arrangements. Those agreements supported U.S. development and commercialization during the branded period.
The current licensing opportunity is limited. A new transaction would be more likely to involve:
- Generic supply rights.
- Regional marketing rights.
- Fixed-dose H. pylori combinations.
- Pediatric formulations.
- Manufacturing technology.
- Rights to a broader gastrointestinal portfolio.
A license for the legacy Aciphex brand alone would have limited strategic value unless it included an established commercial channel or a differentiated formulation.
What manufacturing and IP barriers affect rabeprazole?
Manufacturers must manage rabeprazole’s sensitivity to acidic conditions, product stability and enteric release. Technical barriers include:
- Maintaining active-ingredient stability during granulation and compression.
- Preventing degradation during storage.
- Achieving reproducible delayed release.
- Matching dissolution specifications.
- Controlling coating uniformity.
- Demonstrating bioequivalence.
- Maintaining supply of specialized coating and excipient materials.
These barriers can support manufacturing know-how and quality differentiation, but they do not generally create durable exclusivity once multiple manufacturers have validated equivalent products.
Geographic protection is also uneven. U.S. core patents are expired, while selected countries may retain narrower process, formulation or local regulatory protections. International freedom-to-operate analysis must be conducted country by country.
How does Aciphex compare with newer acid-suppression products?
Vonoprazan is the most important newer competitive technology. It provides potassium-competitive acid blockade and has been developed for H. pylori eradication and erosive esophagitis. Vonoprazan products have more recent patents and regulatory exclusivity than rabeprazole.
| Attribute |
Aciphex/rabeprazole |
Vonoprazan products |
| Drug class |
PPI |
Potassium-competitive acid blocker |
| Core protection |
Expired |
More recent active protection |
| Generic competition |
Established |
More limited |
| H. pylori role |
Combination therapy |
Branded combination products |
| Differentiation |
Limited |
Faster and more sustained acid suppression claims |
| Commercial outlook |
Mature generic |
Growth and life-cycle management potential |
Rabeprazole remains relevant where cost is the main consideration. Vonoprazan has greater proprietary and commercial momentum.
Key Takeaways
- Aciphex is rabeprazole sodium, a mature PPI with expired core exclusivity.
- Generic rabeprazole is widely available in the United States.
- No active branded clinical program is materially expanding Aciphex’s market.
- The product has no meaningful biosimilar risk because rabeprazole is a small molecule.
- Historical compound, formulation and method-of-use patents no longer provide broad U.S. protection.
- Current commercial value lies mainly in generic volume, manufacturing efficiency and selected international markets.
- Brand Aciphex revenue should remain flat to declining.
- Vonoprazan-based products are the principal newer acid-suppression competitors with stronger current IP positions.
- New rabeprazole formulations could obtain narrow patent protection but would face difficult commercial differentiation.
- Active U.S. patent litigation and Paragraph IV risk are low relative to the historical Aciphex launch period.
FAQs About Aciphex Patent and Market Status
Is Aciphex still sold in the United States?
Aciphex has had limited branded commercial relevance since generic rabeprazole became available. Rabeprazole sodium delayed-release tablets remain available primarily through generic manufacturers.
Is rabeprazole available over the counter?
Prescription availability is the standard U.S. channel for rabeprazole. Other PPIs, including omeprazole, esomeprazole and lansoprazole, have stronger OTC positions.
Can a company obtain new patents on rabeprazole?
Yes. New patents could cover a novel formulation, dosage regimen, combination product or manufacturing process. Such patents would not restore broad protection for the original Aciphex product.
Does Aciphex have pediatric exclusivity remaining?
No commercially meaningful pediatric exclusivity remains for the legacy Aciphex product. Pediatric labeling is part of the established regulatory record.
Is Aciphex exposed to biosimilar competition?
No. Rabeprazole is a chemically synthesized small molecule. Generic competition proceeds through the FDA ANDA pathway, not the biosimilar pathway.
References
- U.S. Food and Drug Administration. (2022). FDA approves Voquezna Triple Pak and Voquezna Dual Pak for Helicobacter pylori infection. https://www.fda.gov
- U.S. Food and Drug Administration. (n.d.). Aciphex prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
- United States Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov
- U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov
